Drugs / SH009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07390838 | May 2025 → Dec 2026 expected | breast cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma +2 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07390838 ↗ |